Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences announced today that it has initiated its Phase 1b clinical trial and has also received FDA fast track designation for AU-011 for the treatment of primary ocular melanoma